External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EASL 2026

-
07:30 AM
Duration 8hrs Barcelona, Spain
Patients with compensated MASH cirrhosis and Fibroscan® VCTE score <15 kPa: baseline data from a phase 3, double-blinded, randomized clinical trial assessing the safety and efficacy of pegozafermin (ENLIGHTEN-Cirrhosis)
Rohit Loomba
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 8hrs Barcelona, Spain
Use of the ANTICIPATE NASH risk score to stratify patients with compensated MASH cirrhosis: data from a phase 3, double-blinded, randomized clinical trial assessing the safety and efficacy of pegozafermin (ENLIGHTEN-Cirrhosis)
Juan G Abraldes
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 8hrs Barcelona, Spain
The sequential use of LiverPRO and ADAPT enhances fibrosis detection in at-risk populations
Diana Julie Leeming
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:30 AM
Duration 8hrs Barcelona, Spain
Clinical performance of the Cobas HDV assay for hepatitis D virus RNA detection and quantification for the diagnosis and treatment monitoring of chronic hepatitis D
Marc Lütgehetmann
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon